Lead Product(s) : GLPG5101
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Galapagos Reports Encouraging Results for GLPG5101 in NHL in Phase 1/2
Details : GLPG5101 is an autologous anti-CD19 CAR-T cell therapy candidate, which is currently being evaluated for the treatment of relapsed/refractory non-hodgkin lymphoma.
Product Name : GLPG5101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 07, 2024
Lead Product(s) : GLPG5101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GLPG5301
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GLPG5301 is an autologous, second-generation/4-1BB B-cell maturation antigen (BCMA)-directed CAR-T product candidate which is under phase 1/2 clinical development for the treatment of relapsed/refractory multiple myeloma.
Product Name : GLPG5301
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 19, 2023
Lead Product(s) : GLPG5301
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GLPG5201
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GLPG5201 is an anti-CD19/4-1BB CAR-T product candidate, administered as intravenous infusion. It is being developed for relapsed/refractory chronic lymphocytic leukemia (rrCLL) and small lymphocytic lymphoma (rrSLL).
Product Name : GLPG5201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 02, 2023
Lead Product(s) : GLPG5201
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CYAD-01
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Celyad Oncology Announces the Publication of Data from Its Phase 1 THINK Study Of CYAD-01
Details : CYAD-01 is an autologous CAR T-cell candidate based on the fusion of the NKG2D receptor with CD3ζ. Co-stimulation is ensured by endogenous DAP10. It is being investigated for hematological malignancies, AML, MDS), or multiple myeloma (MM)] and solid tum...
Product Name : CYAD-01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 02, 2023
Lead Product(s) : CYAD-01
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cam-H2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : INKEF Capital
Deal Size : $87.8 million
Deal Type : Series B Financing
Precirix Raises EUR 80m in Series B to Advance Its Pipeline of Precision Radiopharmaceuticals
Details : The proceeds of this financing round will fund the development and expansion of Precirix’ pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study and plans to bring additional novel radiopharmaceuticals to the ...
Product Name : Cam-H2
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : Cam-H2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : INKEF Capital
Deal Size : $87.8 million
Deal Type : Series B Financing
Lead Product(s) : Cam-H2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CAM-H2 comprises a single-domain antibody targeting HER2, covalently linked to iodine-131. Single-domain antibodies are ideally suited for targeted delivery of radiation to tumors given their size for the treatment of HER2-positive metastatic cancer.
Product Name : Cam-H2
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : Cam-H2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : European Commission
Deal Size : $8.3 million
Deal Type : Funding
Consortium Led by etheRna Immunotherapies Awarded Eu Commission Tiger Grant of Eur 6.9 Million
Details : The grant will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic HPV16+ cancers such as head and neck cancer, cervical cancer, anogenital cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 22, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : European Commission
Deal Size : $8.3 million
Deal Type : Funding